Home > Insider Trading > Filing (0001209191-21-005395)

Filing Details

Accession Number:: 0001209191-21-005395
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2021-01-26 16:56:19
Reporting Period:: 2021-01-22

Accepted Time:: 2021-01-26 16:56:19
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1357874	Precision Biosciences Inc	DTIL	Biological Products, (No Disgnostic Substances) (2836)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1769887	R. Matthew Kane	C/O Precision Biosciences, Inc. 302 E. Pettigrew Street, Suite A-100 Durham NC 27701	President And Ceo	Yes	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2021-01-22	21,514	$0.04	1,840,592	No	4	M	Direct
Common Stock	Disposition	2021-01-22	10,218	$13.53	1,830,374	No	4	S	Direct
Common Stock	Acquisiton	2021-01-25	21,514	$0.04	1,851,888	No	4	M	Direct
Common Stock	Disposition	2021-01-25	9,695	$13.74	1,842,193	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Employee Stock Option (Right to Buy)	Disposition	2021-01-22	21,514	$0.00	21,514	$0.04
Common Stock	Employee Stock Option (Right to Buy)	Disposition	2021-01-25	21,514	$0.00	21,514	$0.04

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
301,197		2021-05-17	No	4	M	Direct
279,683		2021-05-17	No	4	M	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	9,752	Indirect	By Spouse

Footnotes

Includes 6,651 additional shares acquired under the Company's 2019 Employee Stock Purchase Plan since the reporting person's ownership report filed on September 25, 2019.
The sales were effected pursuant to a Rule 10b5-1 plan. The transaction was a sell-to-cover exercise for an option grant expiring 05/17/2021, with shares sold to cover the option exercise price and taxes, and the reporting person retaining all remaining shares.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.50 to $13.60. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.70 to $13.86. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Includes 1,685 additional shares acquired under the Company's 2019 Employee Stock Purchase Plan since the reporting person's ownership report filed on September 25, 2019.
Shares are held by Chelsea Lynam Kane, the spouse of the reporting person. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.
The option is fully vested and exercisable.